Director/PDMR Shareholding

RNS Number : 4394P

Advanced Oncotherapy PLC

08 June 2015

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Director/PDMR Shareholding

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Sanjeev Pandya, Chief Executive Officer, and Nicolas Serandour, Chief Financial Officer, informed the Company on 5 June 2015 that they individually purchased 220,000 ordinary shares of 1 penny each in the Company ("Ordinary Shares") at 9 pence per Ordinary Share on that day.

In addition, the Company was informed on 5 June 2015 that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, purchased 1,500,000 Ordinary Shares at 9.81 pence per Ordinary Share on 3 June 2015.

Following these transactions Sanjeev Pandya now holds 590,400 Ordinary Shares representing 0.044% of the issued share capital of the Company, Nicolas Serandour now holds 220,000 Ordinary Shares representing 0.016%. Michael Bradfield now has a total beneficial interest in 122,018,510 Ordinary Shares representing 8.941%.

Advanced Oncotherapy Plc	www.avoplc.com
Sanjeev Pandya, CEO	Tel: [phone]
Nicolas Serandour, CFO
Westhouse Securities (Nomad & Joint Broker)
Antonio Bossi / David Coaten	Tel: [phone]
Beaufort Securities (Joint Broker)
Saif Janjua / Jon Levinson	Tel: [phone]
Walbrook PR (Financial PR & IR)	Tel: [phone] or [e-mail]
Paul McManus / Anna Dunphy	Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

The Company has signed a purchase agreement with Sinophi Healthcare Limited for one LIGHT proton therapy system to be installed in a hospital in China and has further Letters of Intent from other healthcare providers.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

RDSBLGDLSXGBGUU